ArticlePloS one2014
Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Dynamic Changes in Plasma MicroRNAs Have Potential Predictive Values in Monitoring Recurrence and Metastasis of Nasopharyngeal Carcinoma.BioMed research international · 2018Trial
- Exercise - induced changes in cerebrospinal fluid miRNAs in Gulf War Illness, Chronic Fatigue Syndrome and sedentary control subjects.Scientific reports · 2017Trial
- Serum-MiR-CanPred: deep learning framework for pan-cancer classification and miRNA-targeted drug discovery.RNA biology · 2025Article
- The regulation of LRPs by miRNAs in cancer: influencing cancer characteristics and responses to treatment.Cancer cell international · 2025Review
- Expansion of plasma MicroRNAs over the first month following human stroke.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Downregulation of miR-451 in cholangiocarcinoma help the diagnsosi and promotes tumor progression.BMC molecular and cell biology · 2022Article
- Diagnostic Potential of Exosomal microRNAs in Colorectal Cancer.Diagnostics (Basel, Switzerland) · 2022Article
- Long Non-Coding RNAs in Pancreatic Cancer: Biologic Functions, Mechanisms, and Clinical Significance.Cancers · 2022Review
- Niclosamide induces miR-148a to inhibit PXR and sensitize colon cancer stem cells to chemotherapy.Stem cell reports · 2022Article
- Article
- miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B.Molecular medicine reports · 2021Article
- Plasma exosomal miR-596: a novel biomarker predicts survival in patients with idiopathic pulmonary artery hypertension.The Journal of international medical research · 2021Article
- miR-451: A Novel Biomarker and Potential Therapeutic Target for Cancer.OncoTargets and therapy · 2019Review
- Novel biomarkers for patient stratification in colorectal cancer: A review of definitions, emerging concepts, and data.World journal of gastrointestinal oncology · 2018Review
- Article
- Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib.Clinical and translational medicine · 2017Article
- Identification of potential long non-coding RNA biomarkers associated with the progression of colon cancer.Oncotarget · 2017Article
- The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy.Digestive diseases and sciences · 2017Article
- The biology of uveal melanoma.Cancer metastasis reviews · 2017Review
- Diagnostic and Prognostic Value of miR-1287 in Colorectal Cancer.Journal of gastrointestinal cancer · 2016Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
Systemic treatment of patients with early-stage cancers attempts to eradicate occult metastatic disease to prevent recurrence and increased morbidity. However, prediction of recurrence from an analysis of the primary tumor is limited because disseminated cancer cells only represent a small subset of the primary lesion. Here we analyze the expression of circulating microRNAs (miRs) in serum obtained pre-surgically from patients with early stage colorectal cancers. Groups of five patients with and without disease recurrence were used to identify an informative panel of circulating miRs using quantitative PCR of genome-wide miR expression as well as a set of published candidate miRs. A panel of six informative miRs (miR-15a, mir-103, miR-148a, miR-320a, miR-451, miR-596) was derived from this analysis and evaluated in a separate validation set of thirty patients. Hierarchical clustering of the expression levels of these six circulating miRs and Kaplan-Meier analysis showed that the risk of disease recurrence of early stage colon cancer can be predicted by this panel of miRs that are measurable in the circulation at the time of diagnosis (P = 0.0026; Hazard Ratio 5.4; 95% CI of 1.9 to 15).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.